Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neurocrine Biosciences (NBIX) Equity Income (2019 - 2025)

Neurocrine Biosciences' Equity Income history spans 7 years, with the latest figure at $2.7 million for Q4 2025.

  • For Q4 2025, Equity Income rose 242.11% year-over-year to $2.7 million; the TTM value through Dec 2025 reached -$4.0 million, up 89.22%, while the annual FY2025 figure was -$4.0 million, 89.22% up from the prior year.
  • Equity Income reached $2.7 million in Q4 2025 per NBIX's latest filing, down from $30.6 million in the prior quarter.
  • In the past five years, Equity Income ranged from a high of $37.3 million in Q2 2023 to a low of -$40.1 million in Q3 2023.
  • Average Equity Income over 5 years is $2.1 million, with a median of $1.6 million recorded in 2024.
  • Peak YoY movement for Equity Income: soared 2742.86% in 2022, then tumbled 2012.5% in 2025.
  • A 5-year view of Equity Income shows it stood at $28.4 million in 2021, then plummeted by 74.65% to $7.2 million in 2022, then surged by 302.78% to $29.0 million in 2023, then crashed by 106.55% to -$1.9 million in 2024, then surged by 242.11% to $2.7 million in 2025.
  • Per Business Quant, the three most recent readings for NBIX's Equity Income are $2.7 million (Q4 2025), $30.6 million (Q3 2025), and -$6.7 million (Q2 2025).